Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events - Summary - MDSpire
Advertisement
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
To evaluate the safety of brexpiprazole in patients with agitation associated with dementia due to Alzheimer’s disease, focusing on the timing and duration of treatment-emergent adverse events (TEAEs) and their clinical significance.
Key Findings:
Adverse events occurred at similar times and durations for brexpiprazole (2 or 3 mg/day) and placebo, with specific rates provided.
Participants discontinued placebo treatment earlier due to adverse events compared to brexpiprazole, highlighting the comparative tolerability.
Brexpiprazole remained well tolerated over a total of up to 24 weeks in extension trials, with no significant cognitive decline.
Common adverse events included insomnia (3.7%), somnolence (3.4%), nasopharyngitis (2.7%), and urinary tract infection (2.6%), with low incidence of serious TEAEs.
Interpretation:
Brexpiprazole appears to be a well-tolerated option for managing agitation in Alzheimer’s patients, with a favorable safety profile compared to placebo, suggesting its potential role in clinical practice.
Limitations:
The analysis is based on pooled data from clinical trials, which may not fully represent real-world scenarios and could introduce biases.
Ethics approval was not required for post hoc analyses, potentially limiting the robustness of findings and their generalizability.
Conclusion:
Brexpiprazole is a promising treatment for agitation in Alzheimer’s disease, demonstrating tolerability and safety over extended treatment periods, which is crucial for managing older patients.
